Business context and reporting period
Celsion Corporation’s unaudited Form 10-Q covers the quarter and six months ended June 30, 2017. The company is a development-stage oncology drug company with no meaningful product sales. Its lead candidate, ThermoDox, was in Phase III testing for liver cancer and Phase II testing for recurrent chest-wall breast cancer; GEN-1 was in early-stage ovarian cancer testing.
Key financial metrics
| Metric | Three months ended June 30, 2017 | Six months ended June 30, 2017 |
|---|---|---|
| Licensing revenue | $125,000 | $250,000 |
| Research and development | $3.05 million | $6.52 million |
| General and administrative | $1.65 million | $3.12 million |
| Net loss | $4.89 million | $10.05 million |
| Net loss attributable to common shareholders | $5.24 million | $10.40 million |
| Basic and diluted loss per share | $0.79 | $1.75 |
Revenue was amortization of a prior Hisun technology payment, not product sales. Operating margins are not meaningful given the company’s development-stage status and minimal revenue.
- Cash and cash equivalents were $3.63 million at June 30, up from $2.62 million at December 31, 2016; available-for-sale investments were zero, versus $1.68 million at year-end.
- Operating cash use was $7.33 million for the first half, compared with $8.99 million in 2016. Investing activities provided $1.76 million and financing activities provided $6.57 million.
- Current assets were $3.74 million and current liabilities $6.96 million, a $3.22 million working-capital deficit. Stockholders’ equity was $6.65 million; accumulated deficit was $251.43 million.
- The Hercules loan, including end-of-term charges, was paid in full in June. No loan balance remained at period-end.
Changes versus prior comparable periods
- Second-quarter net loss increased to $4.89 million from $4.53 million in 2016, despite operating expenses declining 3.5% to $4.70 million. The change in the earn-out liability moved from a $409,000 benefit in Q2 2016 to a $292,000 non-cash charge in Q2 2017.
- First-half net loss improved to $10.05 million from $10.25 million. Operating expenses fell 5.2% to $9.64 million, including lower R&D and G&A costs. The earn-out revaluation was a $576,000 charge in 2017 versus a $106,000 benefit in 2016.
- First-half financing included $4.25 million net proceeds from common stock sales and $4.92 million from warrant exercises, partly offset by $2.60 million in debt principal and end-of-term payments. Warrant repricings generated about $3.0 million gross proceeds and a $346,000 deemed dividend.
Outlook, commentary and risks
- Management disclosed substantial doubt about the company’s ability to continue as a going concern over the next 12 months, citing recurring losses, capital needs and lack of committed financing. The filing gives differing estimates for the post-financing cash runway: through year-end 2017 in one discussion and into Q1 2018 in another.
- After quarter-end, the company reported a July registered direct offering and concurrent warrant placement totaling approximately $5.04 million gross. Management also cited a $7.5 million ATM facility and plans to seek further equity, debt, partnerships or licensing. Additional capital may be dilutive; without funding, programs could be delayed, reduced or terminated.
- On August 7, 2017, the OPTIMA Study monitoring committee recommended continuing the trial as planned after reviewing the first 275 patients. Enrollment was reported above 60%, with completion expected by mid-2018 based on then-current rates. The trial’s hypothesis relies partly on post-hoc subgroup analyses of the earlier HEAT study, which failed its primary progression-free-survival endpoint; those retrospective findings are uncertain.
- The company reported positive early OVATION study observations, but these are from a small, early-stage study and do not establish efficacy. Clinical, regulatory, manufacturing, financing, dilution, intellectual-property, competition and Nasdaq-listing risks remain material. The filing reported no legal proceedings and stated disclosure controls were effective.
- A 1-for-14 reverse stock split took effect in May 2017; historical share and per-share figures were adjusted. The $13.76 million EGEN earn-out milestone liability is Level 3 fair value and depends on milestone assumptions.
Important facts for investors to verify
- Actual cash runway after the July financing, operating burn, and whether additional capital was raised on acceptable terms.
- OPTIMA enrollment and timeline, trial conduct and data quality, and the eventual results of the primary overall-survival endpoint.
- Whether ThermoDox’s post-hoc HEAT findings support the current trial hypothesis, given HEAT’s failure on its primary endpoint.
- GEN-1’s progress beyond early-stage observations and the cost and timing of planned studies.
- Potential dilution from outstanding warrants, options, future offerings and the ATM, as well as the assumptions underlying the EGEN earn-out liability.